Trial abstracts in the registry — page 10
700 documents of type trial abstract.
Documents
-
Randomised crossover, phase 1 study of Exenatide in cardiovascular over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low24 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 1 study of Thymosin beta-4 in cardiovascular over as stated in the parent protocol. The Institute holds no reported…
Very low24 Dec 2023 -
Observational, phase 2 study of Thymosin beta-4 in wound healing over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low24 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Thymosin beta-4 in wound healing over as stated in the parent protocol. The Institute holds no reported…
Very low24 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of SS-31 (elamipretide) in mitochondrial disease over as stated in the parent protocol. The Institute holds…
Very low23 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute…
Very low23 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of CagriSema (cagrilintide with semaglutide) in type 2 diabetes and obesity over as stated in the parent…
Very low22 Dec 2023 -
Phase 1 ascending dose, phase 1 study of Kisspeptin-10 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low21 Dec 2023 -
Phase 1 ascending dose, phase 1 study of Teduglutide in mucosal barrier over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low21 Dec 2023 -
Randomised crossover, phase 1 study of Orforglipron in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low20 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Thymosin beta-4 in wound healing randomising 72 participants over 84 days. Primary result: A signal in a…
Low18 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low18 Dec 2023 -
Phase 1 ascending dose, phase 1 study of Tirzepatide in type 2 diabetes and cardiovascular over as stated in the parent protocol. The Institute holds no reported primary…
Very low18 Dec 2023 -
Phase 1 ascending dose, phase 1 study of Tesamorelin in lipodystrophy over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low17 Dec 2023 -
Randomised crossover, phase 1 study of Tirzepatide in obesity and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result…
Very low17 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low16 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Orforglipron in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low16 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in adolescent obesity over as stated in the parent protocol. The Institute holds no reported…
Very low16 Dec 2023 -
Randomised crossover, phase 1 study of Liraglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low15 Dec 2023 -
Randomised crossover, phase 1 study of Tesamorelin in lipodystrophy over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low14 Dec 2023 -
Phase 1 ascending dose, phase 1 study of Lixisenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low14 Dec 2023 -
Single-arm open-label, phase 3 study of Teduglutide in mucosal barrier randomising 59 participants over 24 weeks. Primary result: A reduction in parenteral support…
Moderate13 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 1 study of GHRP-6 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result…
Very low13 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Thymosin beta-4 in wound healing randomising 72 participants over 4 weeks. Primary result: Improvement in…
Low12 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low12 Dec 2023 -
Single-arm open-label, phase 3 study of Tirzepatide in type 2 diabetes over open-label extension of the parent trial. The Institute holds no reported primary result for…
Very low12 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 1 study of CJC-1295 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result…
Very low12 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low11 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Thymosin alpha-1 in immune modulation over as stated in the parent protocol. The Institute holds no…
Very low09 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in type 2 diabetes and chronic kidney disease over as stated in the parent protocol. The…
Very low09 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide, oral in cardiovascular and type 2 diabetes over as stated in the parent protocol. The…
Very low07 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Exenatide in cardiovascular and chronic kidney disease and type 2 diabetes over as stated in the parent…
Very low07 Dec 2023 -
Observational, phase 3 study of Lixisenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low06 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Orforglipron in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low05 Dec 2023 -
Randomised crossover, phase 1 study of GHK-Cu in wound healing over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low05 Dec 2023 -
Single-arm open-label, phase 3 study of Exenatide in type 2 diabetes over open-label extension of the parent trial. The Institute holds no reported primary result for…
Very low03 Dec 2023 -
Phase 1 ascending dose, phase 1 study of Ipamorelin in gastric emptying over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low03 Dec 2023 -
Single-arm open-label, phase 2 study of Glutathione in cognition over open-label extension of the parent trial. The Institute holds no reported primary result for this…
Very low29 Nov 2023 -
Randomised crossover, phase 1 study of Liraglutide in adolescent obesity over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low26 Nov 2023 -
Phase 1 ascending dose, phase 1 study of Tesamorelin in lipodystrophy over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low25 Nov 2023
page 10 of 18